Conclusions
1. The presence of NASH, which occurs in 62.5% of patients with coronary heart disease and type II diabetes, requires reassessment of complex lipid-lowering therapy used in the studied patient groups due to the frequent concomitant liver pathology.
2. Use of Enterosgel in the complex treatment of NASH patients on the background of CHD and type II DM is an effective and safe method of hyperlipidemia correction.
3. Enterosgel helps to eliminate syndrome of lipid distress (lipid distress syndrome-), including diabetic dislipidemia, reduce the activity of systemic inflammation and atherogenic potential of blood plasma.
4. Enterosgel helps to improve the functional state of the liver.
5. Based on the data obtained, absorbent Enterosgel can be considered as an effective means in preventing the progression of the atherosclerotic process in patients with NASH and concomitant coronary artery disease and type II DM.

Keywords: adsorbent, hyperlipidemia, lipoproteins, non-alcoholic steatohepatitis, coronary artery disease, diabetes mellitus, sorption, cholesterol, Enterosgel.